ANVISA approves limited use of Remdesivir; AstraZeneca/Fiocruz vaccines approved for general use

The drug can be used in hospitalized patients over 12 years of age who need oxygen, but are not intubated. The price of the treatment is still high, which hinders its use by the SUS.

RIO DE JANEIRO, BRAZIL - Remdesivir, the first drug approved in Brazil with an indication in the package insert for the treatment of Covid-19, can reduce the hospitalization time for patients with the disease, according to ANVISA, the National Health Regulatory Agency.

Friday, March 12th, the agency authorized the use of the drug in the country in patients over 12 years of age, weighing at least 40kg and suffering from pneumonia requiring oxygen supply, but who are not submitted to invasive mechanical ventilation, such as intubated patients.

It relied on clinical studies that show a reduction of approximately 5 days . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?